Evidence D: Clinical review, prescribing, pharmacy fulfillment
Status: first pass complete, 2026-10-19 (PT). Live probes 2026-10-19 PT / 2026-10-20 UTC. Scope: from a booked GLP-1 visit → clinician review → tirzepatide decision → eRx → pharmacy order → fill/delivery → week-4 titration. Acquisition, signup, intake questionnaire detail, lab ordering detail, and card capture are other evidence files; this file covers only what changes at the clinical/pharmacy handoff. Reader: technology plan + operating plan. Every claim is tagged. Unknowns are explicit.
0. Method, system map, and Corrections
0.1 Sources actually used
- Recovered consumer source:
src/sources/first-party/(routes, RTK evidence files, components, hardcoded category copy). - Internal portal recon:
osint/internal_portals_recon.json(Visitron 98 paths / 91 RTK ops / 33 tags; Catalog 47/106; Referrals 18/27; Provider Chat 20/14). - Live public GETs against
generalmedicine.coand its own/api/external/*proxy (no auth, no forms, no checkout). Prices and pharmacy rows below are live API payloads, not dossier prose. - Public primary sources: Zepbound SPL/label, Mounjaro SPL/label, LillyDirect FAQ, Zepbound savings-card terms, NPPES, Walmart release, Pharmacy Times.
- Dossiers:
architecture.md,api-spec.md,data-models.md,openapi.yaml,adversarial-and-market-report.md,generalmedicine.md, and the briefing appendix.
0.2 System map on this path
| Layer | System | Role | Evidence |
|---|---|---|---|
| Storefront | Next.js 14 App Router (generalmedicine.co) |
GLP-1 eval PDP, visit options, compare-pharmacies drawer, pharmacy directory, pharmacy order UI | [CODE app/…; components/VisitOptions/*; components/ProductDetailPage/*] |
| Core API | Nile-Core, Ruby on Rails (api.generalmedicine.co) |
Visits, prescriptions, pharmacy orders, pricing, care journeys, messaging | [DOC architecture.md §1, §9] |
| Clinician UI | Visitron (visitron.internal.generalmedicine.co, visitron.staging-nile.com) |
Appointment → chart → encounter → care pathway → eRx → benefit check → next-step review → shift checkout | [DATA osint/internal_portals_recon.json → visitron] |
| EHR of record | Athenahealth | Encounter/care-plan write-back, chart resync, patient athena_id |
[CODE Visitron ops sync_encounter_to_athena, care_plan_athena_resync, encounter_summary_athena_resync]; role per [DOC architecture.md §8.2] |
| eRx | DoseSpot | SSO, draft/finalize Rx, patient meds, inbound refill requests, RTPB/formulary | [CODE Visitron ops dose_spot_sso, createDraftPrescription, finalizeDraftPrescription, prescription_eligibility_inquiries/*] |
| Ambient scribe | Nabla | Scribe status only; note drafting | [CODE Visitron op get_nabla_status]; role [DOC architecture.md §8.2] |
| Benefit check | Arrive Health | RTPB launch + patient context; returns copay/formulary/PA signal and arrive_rtpbi_inquiry_id |
[CODE /api/internal_oauth/arrive_health/launch_benefit_inquiry, patient_context]; [CODE lib/store/api/pharmacyOrderApi.ts:99] |
| HIE | Metriport + Particle Health | Longitudinal records, meds, allergies; prewarm | [CODE Visitron op trigger_metriport_sync]; [DOC generalmedicine.md §7] |
| Payments | Stripe | SetupIntent / payment method / checkout | [CODE lib/api/endpoints.ts:321-328]; [LIVE https://generalmedicine.co/terms-of-service, 2026-10-19] |
| Pharmacy IDs | NCPDP provider IDs | Routing key sent on select_pharmacy |
[CODE lib/store/api/pharmacyOrderApi.ts:90-103] |
| Manufacturer pharmacy | LillyDirect Pharmacy, LLC (NCPDP 1574056, NPI 1912889320) |
NCPDP endpoint for Zepbound/Foundayo; actual dispensing by third parties | [LIVE /api/external/pharmacy_detail_pages/88334, 2026-10-19]; [PUBLIC NPPES 1912889320] |
| Manufacturer pharmacy | NovoCare (NCPDP 5758074, NPI 1710671854 = CoAssist Pharmacy, LLC) |
NCPDP endpoint for Wegovy | [LIVE /api/external/pharmacy_detail_pages/84293, 2026-10-19] |
| Mail pharmacy | Amazon Pharmacy (NCPDP 5919177, NPI 1285084467 = A.E. Pharmacy, LLC) |
Mail-order eRx endpoint | [LIVE /api/external/pharmacy_detail_pages/36035, 2026-10-19] |
| Retail | CVS / Walgreens / Walmart / other | Pickup, insurance adjudication, GM card | [CODE components/ProductDetailPage/PharmacyQuickFilters.tsx:11] |
| Payer/PBM | Patient's plan | Claim adjudication, PA, copay | [INFERENCE] from insurance billing type and PA copy |
| Professional entity | Emerald PCs (AZ, CA, KS, ID, NJ per current legal docs) | Furnishing/billing entity for Emerald telehealth | [LIVE /terms-of-service, /telehealth-informed-consent] |
| Delegated network | OpenLoop / Reliant.MD / MECNB under “Vital” consent | Alternative furnishing network, state variants | [LIVE /vital-informed-consent, 2026-10-19] |
0.3 Corrections to the brief and prior dossiers
These are the places where the evidence changes the working assumption. Read these before the tables.
- Chat is cash-only. The GLP-1 evaluation sells chat at $30 cash with no insurance sub-option. Video is $100 cash or $25 estimated insurance. So “insured $25” applies to video (and e-consult), not chat.
[LIVE https://generalmedicine.co/s/glp-1-medication-evaluation/300543, 2026-10-19];[LIVE /api/external/sku_options/300543, 2026-10-19] - ACR is not the GLP-1 pathway. GLP-1 evaluation (
300543) exposes onlyvideoandchat; its price options carry noallows_acrand no in-person option. ACR is a per-option async-review capability (allows_acr) that the code comment associates with in-person SKUs; where enabled,checkout_feebundlescoordination_fee+clinical_review_fee(live example300603: 3000 + 1500 = 4500). The ACR escalation SKU300591is a real follow-up video visit, but it is not the default GLP-1 path.[CODE components/VisitOptions/OfficeVisitOption.tsx:52-57];[CODE types/enums/sku-constants.ts:7-8];[LIVE /api/external/sku_options/300603, 2026-10-19] - Compounded GLP-1 is not offered. No compounded semaglutide/tirzepatide SKU exists in the 3,184-URL sitemap, the live search index, or the recovered source. Searching
compoundedreturns lexical matches (Diclofenac, CombiPatch), not a compounded GLP-1.[DATA osint/live_sitemap_skus.json → sitemap_only_skus];[LIVE /api/external/search/index?query=compounded, 2026-10-19];[CODE grep: no “compounded” in ts/tsx] - The default Zepbound PDP is the most expensive form.
/s/zepbound-tirzepatide/201448canonicalizes to/dp/zepbound/710642, whoseselected_sku_idis the auto-injector at $1,074.09. The KwikPen is a separate option: 2.5 mg$299, 5 mg$399, 7.5–15 mg$449. The “from $299” on the Lilly partner page is the KwikPen/self-pay tier, not the default PDP price.[LIVE /api/external/product_detail_pages/710642, 2026-10-19];[LIVE /api/external/medication_option_skus/710642/cash_price = 107409];[LIVE https://generalmedicine.co/p/lilly/weight-loss, 2026-10-19] - Vials are unpriced and not routed to LillyDirect. “Injectable solution” (single-dose vial) SKUs return
total_price_cents: nulland their pharmacy comparison contains only retail rows (no LillyDirect), even though vials are the canonical LillyDirect self-pay format. The cheapest self-pay format is effectively not purchasable through GM’s storefront.[LIVE /api/external/medication_option_skus/701542/cash_price = null];[LIVE /api/external/pharmacy_comparisons?medication_option_sku_id=701542, 2026-10-19];[LIVE /api/external/pharmacy_detail_pages/88334/medications, 2026-10-19](only710641and706450) - LillyDirect is not one fulfillment partner.
LillyDirect Pharmacy, LLCis the NCPDP endpoint (1574056), but LillyDirect’s own FAQ names Amazon Pharmacy, Fuze Health, Gifthealth, Prescryptive, and Walmart Pharmacy as third-party dispensing pharmacies; the dispensing pharmacy depends on medicine, delivery method, and payment method.[LIVE https://www.lilly.com/lillydirect/faq, 2026-10-19];[PUBLIC NPPES 1912889320 = LILLYDIRECT PHARMACY, LLC, former legal name BALANCE PHARMACY SERVICES LLC] - The Friendly-PC list in the legal docs does not match NPPES. Current Terms (rev. 2026-09-16) and Telehealth Consent name Emerald Medical Practice, P.C. (AZ), Emerald Medical Practice, P.A. (KS), Emerald Medical Practice, P.C. (CA), Ruby Medical Practice, P.C. (NJ), Centennial Medical Practice, P.C. (ID). The NPPES records behind the three known PC names resolve to Emerald (UT, two NPIs), Centennial (FL), Ruby (NJ); I did not find separate AZ/KS/CA/ID enumerations for those names. NPPES may not reflect every state registration, so treat the state→PC matrix as unresolved.
[LIVE /terms-of-service; /telehealth-informed-consent];[PUBLIC NPPES 1447011267, 1750195483, 1174333975, 1346050150] in_stockis not real.data-models.mdincludesPharmacyComparisonResult.in_stock, but the livepharmacy_comparisonspayload has noin_stock, no hours, no city/state, and no tracking. Onlychain_name,fulfillment_owner,ncpdp_provider_id,friendly_id,address_line1,distance_miles,latitude,longitude,total_price_cents. There is no inventory signal to automate out-of-stock handling.[LIVE /api/external/pharmacy_comparisons?medication_option_sku_id=710641&latitude=37.7749&longitude=-122.4194, 2026-10-19]- Billing-type enum is inconsistent client vs server. Client code checks
'gm_card'and'pharmacy_delegated'; the OpenAPI/API spec enum is'cash' | 'insurance' | 'pharmacy_delegation'. Either the server accepts aliases or one branch is dead.[CODE lib/utilities.ts:949-955];[DOC openapi.yaml:257-262, 1241-1246] - “We take care of prior authorizations” is marketing, not a recovered workflow. There is no PA object, queue, or submit operation in the consumer API or Visitron’s 91 ops. Arrive Health and DoseSpot expose RTPB only; no CoverMyMeds/Surescripts/PA vendor is present in source or DNS. The Assignment of Benefits says pre-authorization is the patient/referring physician’s responsibility.
[CODE lib/hardcoded-data/CategoryPages/medications.ts:43];[LIVE /assignment-of-benefits, 2026-10-19];[DATA osint/internal_portals_recon.json → visitron] - The Lilly partner page’s Zepbound CTA points at a SKU that does not allow first fill.
201448hasallows_first_fill: false,allows_refill: true, yet the Lilly page’s Zepbound card links to/s/sku/201448/screen. The new-start path is the GLP-1 evaluation300543. This is a funnel/eligibility mismatch worth fixing or explaining.[DATA osint/extracted_care_plans_and_journeys.json → 201448.modalities];[LIVE https://generalmedicine.co/p/lilly/weight-loss, 2026-10-19] - Catalog quantity/unit is internally inconsistent. For a 28-day weekly injection: Zepbound auto-injector
default_quantity: 2.0“Auto-injectors”; Zepbound KwikPen2.4“Injection pens”; Mounjaro1.0“Auto-injector”. These look like mL totals with a mislabeled unit, and Mounjaro’s 1.0 mL is half of a 4-pen 28-day supply. Do not generate Rx quantity from these fields without verification.[LIVE /api/external/product_detail_pages/710642, 710655, 201448, 2026-10-19]
1. Steps and label-based clinical regimen
Day/time is relative to the organic Google click (D0). this file starts once the patient has chosen a visit; upstream acquisition/intake is out of scope. “T” = scheduled visit start.
Routing summary (direct answer). A GLP-1 case reaches a clinician in one of two ways: (1) a scheduled video visit (video_visit; Zoom; $100 cash / $25 est. insurance), or (2) a chat visit (chat_visit; $30 cash; next available window, live availability promise was next-day 10:00 MT). Both are created at booking and surfaced in Visitron’s appointment/chat queues. GLP-1 does not enter the ACR queue: 300543 has no allows_acr option. If a case were ACR-enabled, Visitron would use getAsyncClinicalReview / submitAsyncClinicalReview, with 300591 as the video escalation. [LIVE /api/external/sku_options/300543]; [DATA internal_portals_recon.json → visitron]; [CODE types/enums/sku-constants.ts:7-8]
| Step | Day/time | Patient sees / does | GM system, screen, route | Data captured / emitted | Evidence |
|---|---|---|---|---|---|
| D1 | D0 + 10–30 min | Opens GLP-1 evaluation page. Sees Video $25 est. / $100 w/o insurance and Chat $30 w/o insurance. Picks modality; picks a slot (video) or accepts next available chat window. | /s/glp-1-medication-evaluation/300543 → /options → POST /api/external/visits/:id/booking_selection → POST /visits/:id/payment_method → POST /visits/book. Visit cart keyed on localStorage['general-ai-visit-id']. |
sku_id=300543; modality video/chat; slot or availability promise; payment method; price shown; state; attribution ref. |
[LIVE https://generalmedicine.co/s/glp-1-medication-evaluation/300543, 2026-10-19]; [LIVE /api/external/sku_options/300543, 2026-10-19]; [CODE lib/api/endpoints.ts:82-92]; [CODE lib/store/api/visitCartApi.ts:58-123] |
| D2 | D0 + 20–30 min | Confirms physical location/state before screening. May be asked for ID and to confirm location again at visit. | /s/{sku-name}/{sku-id}/location-confirmation; appointment_location_state appended to GET /api/external/sku_options/:skuId; server is expected to filter the clinician pool (not directly observed). practiceId carried through booking from the insurance flow. |
state; practice_id; clinician pool; booking eligibility. |
[CODE lib/routes/skuBooking.ts:53-59]; [CODE lib/api/endpoints.ts:132-136]; [CODE lib/redirectFromInsuranceFlow.ts:11-12, 147-181]; [DOC architecture.md §10.6]; [LIVE /telehealth-informed-consent] |
| D3 | D0 (video, promise “today”) or D0+1 ~10:00 MT (chat promise) | Waits; receives SMS/email visit link. For chat, waits for clinician to join the text thread. | Visitron ProviderAppointments / PatientAppointments; getAppointmentInfo; requestChatVisit; getProviderNotifications; open_visit. Patient side uses visit room / Zoom link / chat thread (Twilio Conversations per dossier). |
appointment_id; visit_type; patient_id; clinician_id; state; meeting_url (video). |
[DATA osint/internal_portals_recon.json → visitron.rtk_endpoints]; [LIVE /api/external/sku_options/300543] (availability_promise 2026-10-20T10:00:00-06:00 for chat, today for video); [LIVE https://generalmedicine.co/using-zoom, 2026-10-19] |
| D4 | T − 10 min | Nothing. | Clinician opens chart: applyAppointmentLatestPrewarm, getPatientChartContext, getPastVisits, triggerMetriportSync, getQuestionnaireCodes, getSkus. |
HIE history (Metriport/Particle), prior GM encounters, meds, allergies, questionnaire responses, SKU context. | [DATA osint/internal_portals_recon.json → visitron]; [DOC generalmedicine.md §7]; [DOC architecture.md §8.2] |
| D5 | T to T+15–45 min | Video: joins Zoom, camera required. Chat: exchanges messages in the visit thread; can text 98528 if disconnected. | Visitron getDraftEncounter, updateDraftEncounter, getChatHistory, getNablaStatus, getAdHocEncounterInfo; video transport is Zoom; chat transport is the visit/message thread. |
Transcript/audio; note draft; encounter time; diagnoses discussed; orders; chat messages. | [LIVE /using-zoom] (Zoom app, unique link, 98528); [DATA internal_portals_recon.json → visitron]; [DOC architecture.md §10.2] |
| D6 | During D5 | Describes weight history, prior attempts, comorbidities, current meds, side effects, goals. Clinician screens BMI and contraindications; may order baseline labs. | Clinical decision uses GM’s GLP-1 guide + product labels. Visitron searchDiagnoses, getIcd10Codes, getLabCodes, getQuestionnaireCodes; orders via Orders / getEncounterOrders. |
Height, weight, BMI (Zepbound weight-management criteria: BMI ≥30, or ≥27 with a weight-related comorbidity; Mounjaro is T2D and has no BMI threshold); comorbidities (HTN, dyslipidemia, T2D, OSA, CVD); label §4 contraindications (MTC/MEN2, serious hypersensitivity); protocol precautions (pancreatitis, gastroparesis, eating disorder, pregnancy); prior GLP-1; baseline labs (HbA1c, CMP, TSH, lipids). | [LIVE https://generalmedicine.co/resources/using-a-glp-1-for-weight-loss, 2026-10-19]; [PUBLIC Zepbound SPL §1, §2.2, §4]; [PUBLIC Mounjaro SPL §1, §2.1]; [DATA internal_portals_recon.json → visitron] |
| D7 | During/after D5 | Nothing directly; later sees care-plan phases/check-ins. | Visitron getPublishedPathways, createCareJourney, changePathway, changePhase, batchChangePatientMedicationPhases, updatePatientMedicationDaysSupply, updatePatientMedicationCourseType. Catalog authors care_pathways, sku_phases, phase_modality, criteria_sets, requirements. |
pathway_id; phase_id; modality; check-in cadence; days supply; course type. |
[DATA internal_portals_recon.json → visitron, catalog]; [DOC generalmedicine-executive-briefing.html App. F.06] (5-phase synthesis) |
| D8 | T+30–60 min | Nothing; later sees prescription in care plan. | Visitron createDraftPrescription → updateDraftPrescription → finalizeDraftPrescription; replaceDraftPrescription; cancelDraftPrescription; createPatientMedicationPrescriptionRenewal; DoseSpot SSO (dose_spot_sso) and getDoseSpotIdpStatus. |
Drug (tirzepatide), strength (2.5/5/7.5/10/12.5/15 mg), form (KwikPen/auto-injector/vial), quantity, days supply (28), refills, SIG, diagnosis, later pharmacy NCPDP ID. | [DATA internal_portals_recon.json → visitron]; [CODE /api/internal_oauth/visitron/dose_spot_sso]; [PUBLIC Zepbound SPL §2.2] |
| D9 | T+30 min → D+5 business days | Sees “available after visit” / “est. insurance price”; later may see copay or PA request. | Visitron launchInsurancePrice, getInsurancePriceStatus, launch_benefit_inquiry, getDoseSpotIdpStatus, DoseSpot prescription_eligibility_inquiries/{launch,formulary,sync_insurance}. Consumer polls /api/external/pharmacy_pricing/insurance/:inquiryId. |
Copay tier; deductible; formulary status; PA required; arrive_rtpbi_inquiry_id; plan/payer name. |
[CODE components/ProductDetailPage/MedicationPriceCard.tsx:14-15]; [CODE lib/api/endpoints.ts:345-348]; [DATA internal_portals_recon.json → visitron]; [LIVE /dp/zepbound/710642] (“Available after visit”); [LIVE GLP-1 guide] (“several business days”) |
| D10 | T+45–60 min | Later sees signed care plan/next steps. | Visitron confirmCarePlan, publishAppointmentDraftEncounter, syncEncounterToAthena, generateNextStepReview, createNextStepReview, updateNextStepReview; resync ops. |
Signed encounter note; care plan; orders; athena_id; next-step review. |
[DATA internal_portals_recon.json → visitron]; [DOC architecture.md §8.2] |
| D11 | D+1–24 h (patient action) | Opens prescription in care plan/dashboard; taps to order. | POST /api/external/prescriptions/:careActionPrescriptionId/ensure_pharmacy_order → { pharmacy_order_id }; order state created per the client data model. |
care_action_prescription_id; pharmacy_order_id; medication_sku_id; state=created. |
[CODE lib/store/api/prescriptionApi.ts:24-32]; [CODE lib/api/endpoints.ts:235-240]; [DOC architecture.md §9.1 step 1]; [DOC data-models.md §2.4] |
| D12 | D+1–24 h | Opens “Compare pharmacies”; sees the featured manufacturer pharmacy (LillyDirect or NovoCare, when present) and Amazon pinned ahead of the nearby/online interleave; nearby retail is interleaved 2:1. Selects a pharmacy. | GET /api/external/pharmacy_comparisons?medication_option_sku_id=&latitude=&longitude=; POST /api/external/pharmacy_orders/:id/select_pharmacy with ncpdpProviderId + optional arrive_rtpbi_inquiry_id. |
NCPDP ID; total_price_cents; fulfillment_owner; distance; friendly_id; inquiry ID. |
[CODE lib/store/api/pharmacyComparisonApi.ts:13-21]; [CODE lib/api/endpoints.ts:120-124]; [CODE lib/store/api/pharmacyOrderApi.ts:90-103]; [CODE components/Refresh/SearchResults/searchPharmaciesUtils.ts:22-28, 140-155] |
| D13 | D+1–24 h | Chooses cash / GM card, insurance, or pay at pharmacy. | PATCH /api/external/pharmacy_orders/:id { billing_type }. Client checks gm_card, insurance, pharmacy_delegated; server enum is cash, insurance, pharmacy_delegation. |
billing_type; payment method; insurance estimate; hasClinicalReview flag (source of flag not recovered). |
[CODE lib/utilities.ts:949-955]; [CODE lib/store/api/pharmacyOrderApi.ts:34-44]; [DOC openapi.yaml:1232-1246]; [DOC architecture.md §9.1 step 4] |
| D14 | D+1–24 h | Cash: pays GM by card; gets a prepaid card by text. Insurance: no app charge; pays copay at counter. Pay-at-pharmacy: shows GM card at counter. | POST /pharmacy_orders/:id/checkout (Stripe) or /checkout_with_insurance or /checkout_for_pharmacy_delegation; GET /pharmacy_orders/:id/gm_card; GET /invoice. |
payment_method_id; return_url; payment_intent; gm_card { bin, pcn, group, member_id }. |
[CODE lib/store/api/pharmacyOrderApi.ts:61-118]; [DOC openapi.yaml:1338-1420]; [LIVE https://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup, 2026-10-05] |
| D15 | At/after checkout | Nothing; pharmacy receives Rx. | DoseSpot eRx → selected NCPDP ID; select_pharmacy is the routing trigger. Transmission protocol is not visible in the client. |
Rx payload; NCPDP ID; patient demographics; prepaid/discount status. | [CODE lib/store/api/pharmacyOrderApi.ts:90-103]; [DATA internal_portals_recon.json → visitron escribe]; [INFERENCE] NCPDP SCRIPT via DoseSpot, based on DoseSpot eRx + NCPDP IDs |
| D16 | Same day–5 business days | Retail: gets pickup notification. LillyDirect: gets text/email from dispensing pharmacy, then a checkout link; pays the pharmacy. | Retail pharmacy system adjudicates/dispenses. LillyDirect dispensing pharmacy verifies, checks insurance/PA, applies savings, sends checkout link, ships. | Rx status; copay; PA status; checkout link; savings applied; shipment. | [LIVE https://www.lilly.com/lillydirect/faq, 2026-10-19] (3–5 business days verification; dispensing pharmacy contacts patient); [LIVE /pharmacy/walgreens-pharmacy/73542] |
| D17 | 1–4 days after checkout (LillyDirect); same day (retail) | Receives package or picks up. Most LillyDirect shipments do not require a signature; refrigerated packages may have specific delivery requirements. | No GM shipping object. Cold chain handled by dispensing pharmacy. | Tracking (pharmacy-side); delivery confirmation; no GM fields observed. | [LIVE LillyDirect FAQ] (free delivery; 1–4 days; cold-chain; most shipments no signature); [PUBLIC Zepbound SPL §16.2]; [PUBLIC Mounjaro SPL §16.2] |
| D18 | Day 28 of dosing | Gets a check-in card/notification. Completes questionnaire and/or labs; may book a follow-up. | GET /api/external/care_journey/next_steps → 3 groups (Questionnaire, Lab, Visit) with locked, available_at, soonest_deadline, estimated_minutes; /prescriptions/:id/check-in; POST /care_journey/lab_bundle; POST /patient_medications/:id/lab_bundle; POST /visits/.... |
Criteria IDs; questionnaire responses; lab order ID; visit ID; deadline. | [CODE lib/store/api/careJourneyApi.ts:39-83]; [CODE lib/careJourney.ts:1-2]; [CODE lib/prescriptions/prescriptionCheckInFlow.ts:1-100]; [LIVE GLP-1 guide] (“monthly while titrating”) |
| D19 | Day 28 | Follow-up visit: Chat $30 cash or Video $25 est. / $100 cash. Clinician reviews tolerance and adjusts dose per label (usually 2.5 → 5 mg after 4 weeks). | Visitron getClinicianReviews, applyReview, rejectReview, confirmNoChange, changePhase, createPatientMedicationPrescriptionRenewal, createDraftPrescription, finalizeDraftPrescription. |
New dose (e.g., 2.5 → 5 mg), new Rx, phase change, days supply, refills. | [DATA internal_portals_recon.json → visitron]; [PUBLIC Zepbound SPL §2.2]; [LIVE https://generalmedicine.co/s/weight-loss-follow-up/300550] |
| D20 | Day 28–32 | Chooses pharmacy and pays again for the 5 mg fill. | Same as D11–D17. | New order; new NCPDP ID; new price ($399 KwikPen/self-pay; $1,074.09 auto-injector; or insurance copay). | [LIVE /api/external/medication_option_skus/710643/cash_price = 39900]; [LIVE /api/external/medication_option_skus/710646/cash_price = 107409] |
Timing note. “4 weeks into tirzepatide” is 28 days of dosing, not 28 days from first click. If the first fill lands 2–5 days after the visit, D18–D20 are D+30 to D+35 from the click. The label’s week-4 step is the trigger, not a calendar reminder. [PUBLIC Zepbound SPL §2.2]
1.1 Label-based tirzepatide regimen (the clinical decision)
Zepbound — weight reduction / OSA. [PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §§1–2, 4–5, 8.1]
| Element | Label instruction |
|---|---|
| Indication (weight) | Adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition; adjunct to a reduced-calorie diet and increased physical activity. |
| Indication (OSA) | Moderate-to-severe obstructive sleep apnea in adults with obesity. |
| Starting dose | 2.5 mg subcutaneously once weekly for 4 weeks. The 2.5 mg dose is for treatment initiation and is not a maintenance dosage. |
| First escalation | After 4 weeks, increase to 5 mg subcutaneously once weekly. |
| Further titration | Increase in 2.5 mg increments only after at least 4 weeks on the current dose; consider treatment response and tolerability; if a maintenance dose is not tolerated, consider a lower maintenance dose. |
| Maintenance (weight) | 5 mg, 10 mg, or 15 mg subcutaneously once weekly. |
| Maintenance (OSA) | 10 mg or 15 mg subcutaneously once weekly. |
| Maximum | 15 mg subcutaneously once weekly for all indications. |
| Administration | Once weekly at any time of day, with or without meals; abdomen, thigh, or upper arm; rotate injection sites. |
| Missed dose | Take within 4 days (96 hours) of the missed dose; if more than 4 days have passed, skip and resume the regular day. The weekly day can change if at least 3 days (72 hours) separate doses. |
| §4 contraindications | Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); known serious hypersensitivity to tirzepatide or any excipient. |
| §5 precautions (not §4) | Severe GI adverse reactions; not recommended in severe gastroparesis; acute kidney injury from volume depletion; acute gallbladder disease; acute pancreatitis (discontinue if suspected); hypersensitivity reactions; hypoglycemia with insulin/secretagogue; diabetic retinopathy complications in T2D; pulmonary aspiration during general anesthesia/deep sedation; never share a KwikPen. |
| Pregnancy | May cause fetal harm; discontinue when pregnancy is recognized; counsel on non-oral contraception or a barrier method for 4 weeks after initiation and after each dose escalation. |
Mounjaro — type 2 diabetes. [PUBLIC Mounjaro SPL §1, §2.1 (DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0)]
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus.
- 2.5 mg subcutaneously once weekly starting dose; after 4 weeks increase to 5 mg once weekly; if additional glycemic control is needed, 2.5 mg increments after at least 4 weeks on the current dose.
- Maximum 15 mg once weekly in adults; 10 mg once weekly in pediatric patients 10 years and older.
- No BMI threshold — the Zepbound BMI criteria do not apply to Mounjaro.
What GM’s public guide adds (screening, not label). BMI ≥30 or ≥27 with a weight-related condition; screen for MTC/MEN2, pancreatitis, gastroparesis, eating disorder, pregnancy; baseline HbA1c/CMP/TSH/lipids; monthly visits during titration, then roughly every 3 months. These are GM clinical-protocol choices; only MTC/MEN2 and serious hypersensitivity are label §4 contraindications. [LIVE https://generalmedicine.co/resources/using-a-glp-1-for-weight-loss, 2026-10-19]
2. Handoffs table
One row per GM ↔ outside-party exchange on this path. “Who pays” is the payer of the counterparty’s service, not the patient’s drug cost unless stated.
| Handoff | Counterparty (company + product) | Direction | What is exchanged (fields) | Mechanism | Trigger | Who pays / fee | Evidence |
|---|---|---|---|---|---|---|---|
| H1 | Emerald Medical Practice, P.C./P.A. (AZ, CA, KS per current docs) | GM → PC | Clinician identity/NPI; state license; patient encounter; signed order; billing | Employment/1099 contract + Visitron assignment; PC is the furnishing/billing entity | Patient booked in a state served by an Emerald PC | Patient pays visit fee/copay to PC/GM; PC bills insurer | [LIVE /terms-of-service; /telehealth-informed-consent; /assignment-of-benefits]; [LIVE https://generalmedicine.co/clinician-hiring] |
| H2 | Ruby Medical Practice, P.C. (NJ), Centennial Medical Practice, P.C. (ID) | GM → PC | Same as H1 | Same as H1 | Patient in NJ/ID (or as configured) | Same as H1 | [LIVE /terms-of-service; /telehealth-informed-consent]; [PUBLIC NPPES 1346050150, 1174333975] |
| H3 | OpenLoop Healthcare Partners, PC / Reliant.MD / MECNB (under “Vital” consent) | GM → delegated network | Patient, encounter, consent, treatment | Professional-network contract; state-specific PCs; telehealth consent | If patient state/service is routed to delegated network (exact trigger not observed) | Network entity bills; GM coordinates | [LIVE /vital-informed-consent, 2026-10-19]; [DOC adversarial-and-market-report.md §3.1] |
| H4 | Athenahealth | GM → Athena | Encounter note, diagnoses, orders, care plan, patient athena_id |
REST API (sync_encounter_to_athena, care_plan_athena_resync, encounter_summary_athena_resync) |
Clinician publishes/signs encounter | GM license | [DATA internal_portals_recon.json → visitron]; [DOC architecture.md §8.2] |
| H5 | DoseSpot | GM ↔ DoseSpot | Patient meds, draft/final Rx, EPCS identity, formulary, eligibility, inbound refill requests | SSO + REST (dose_spot_sso, prescription_eligibility_inquiries/*, escribe/*) |
Clinician prescribes or refills | GM license | [DATA internal_portals_recon.json → visitron]; [DOC architecture.md §8.2] |
| H6 | Nabla | GM ↔ Nabla | Audio/transcript → note draft; status | Embedded scribe; only get_nabla_status recovered |
Clinician starts scribe | GM license | [DATA internal_portals_recon.json → visitron]; [DOC architecture.md §8.2] |
| H7 | Arrive Health | GM ↔ Arrive | Patient + drug + pharmacy → copay, deductible, formulary, PA signal; arrive_rtpbi_inquiry_id |
OAuth launch + REST (launch_benefit_inquiry, patient_context, pharmacy_pricing/insurance) |
Clinician price check / patient pharmacy selection | GM per-transaction fee (amount unknown) | [DATA internal_portals_recon.json → visitron; catalog]; [CODE lib/store/api/pharmacyOrderApi.ts:99] |
| H8 | Metriport + Particle Health | GM ← HIE | Longitudinal records, meds, allergies, prior encounters | REST (trigger_metriport_sync), prewarm |
Chart prep / General AI prewarm | GM license | [DATA internal_portals_recon.json → visitron]; [DOC generalmedicine.md §7] |
| H9 | Stripe | GM ↔ Stripe | Card token, SetupIntent, payment method, charge, refund | Stripe.js/Elements; payment_method_id; return_url |
Visit payment / pharmacy pre-pay | Patient pays; GM pays Stripe processing | [CODE lib/api/endpoints.ts:321-328]; [LIVE /terms-of-service] |
| H10 | LillyDirect Pharmacy, LLC (NCPDP 1574056) |
GM → LillyDirect | Rx, patient name/DOB/contact, NCPDP ID, payment/insurance context | eRx to NCPDP ID; phone/fax fallback; LillyDirect’s dispensing pharmacy contacts patient | Patient selects LillyDirect | GM pay-ahead is not available at mail order; patient pays the LillyDirect dispensing pharmacy | [LIVE /api/external/pharmacy_detail_pages/88334]; [LIVE LillyDirect FAQ]; [LIVE pay-ahead article] |
| H11 | Amazon Pharmacy (NCPDP 5919177, A.E. Pharmacy, LLC) |
GM → Amazon | Same as H10 | eRx to NCPDP ID | Patient selects Amazon | Patient pays Amazon | [LIVE /api/external/pharmacy_detail_pages/36035]; [PUBLIC NPPES 1285084467] |
| H12 | NovoCare (NCPDP 5758074, CoAssist Pharmacy, LLC) |
GM → NovoCare | Same as H10, for Wegovy | eRx to NCPDP ID | Patient selects NovoCare | Patient pays NovoCare | [LIVE /api/external/pharmacy_detail_pages/84293]; [PUBLIC NPPES 1710671854] |
| H13 | CVS / Walgreens / Walmart / other retail | GM → pharmacy | Rx, NCPDP ID, patient demographics, prepaid notice or GM card | eRx + NCPDP; GM card BIN/PCN; payment card texted for pre-pay | Patient selects retail | Cash: patient pays GM or pharmacy; insurance: PBM pays pharmacy, patient pays copay | [CODE select_pharmacy; gm_card]; [LIVE /pharmacy/walgreens-pharmacy/73542]; [LIVE pay-ahead article] |
| H14 | PBM / payer | Pharmacy ↔ PBM | Claim, member ID, NDC, days supply, copay, PA | NCPDP Telecommunication Standard (inferred) | Fill/adjudication | PBM pays pharmacy; patient pays copay | [INFERENCE] from insurance billing type and PA copy; [LIVE /assignment-of-benefits] |
| H15 | Lilly / Novo savings programs | Manufacturer → pharmacy/patient | Savings card BIN/PCN; eligibility; PTR claim | Pharmacy claim + manufacturer PTR (EVERSANA at eversana-ptr.virtualrx.co) |
Eligible insured or self-pay fill | Manufacturer funds; patient pays reduced copay | [LIVE https://zepbound.lilly.com/savings, 2026-10-19]; [LIVE LillyDirect FAQ] |
| H16 | LillyDirect dispensing pharmacy | Pharmacy → patient | Verification, checkout link, price, delivery/pickup options, tracking | SMS/email; checkout chat | Rx received | Patient pays pharmacy | [LIVE LillyDirect FAQ] |
| H17 | Retail/LillyDirect pharmacy | Pharmacy → GM | Inbound refill request, Rx status, rejection/PA request | eRx inbound (EscribingInboundRequest), fax, phone; GM message center subject pharmacy_order |
Refill/claim issue | No direct fee | [DATA internal_portals_recon.json → visitron]; [CODE lib/store/api/messageCenterApi.ts:19] |
| H18 | GM care/ops → payer | GM → payer | PA form, chart evidence, letter of medical necessity, appeal | Unknown: payer portal/fax/phone; Arrive ePA possible but not evidenced | PA required/denied | GM staff time | [CODE lib/hardcoded-data/CategoryPages/medications.ts:43]; [LIVE /assignment-of-benefits]; [INFERENCE] |
Mechanism note. The only routing key visible in the client is the NCPDP provider ID. The actual eRx transport (NCPDP SCRIPT 10.x via DoseSpot/Surescripts) is server-side and not observed. Do not build an integration plan that assumes GM exposes the raw eRx payload; it does not. [INFERENCE]
3. Ops touchpoints
Where a human acts, with the queue/tool and the SLA signal actually observed.
Who furnishes the visit. The current legal docs assign Emerald telehealth to five PCs: Emerald Medical Practice, P.C. (AZ), Emerald Medical Practice, P.A. (KS), Emerald Medical Practice, P.C. (CA), Ruby Medical Practice, P.C. (NJ), Centennial Medical Practice, P.C. (ID). NPPES records behind the three known PC names resolve to UT/FL/NJ; the Vital consent adds OpenLoop Healthcare Partners, PC / Reliant.MD / MECNB and state variants. The exact state→entity routing is server-side (appointment_location_state, practiceId) and unresolved. Treat it as a config matrix, not a hardcoded list. [LIVE /terms-of-service; /telehealth-informed-consent; /vital-informed-consent]; [PUBLIC NPPES]
| Role | Where they sit | Queue / tool | What they do on this path | SLA / signal | Evidence |
|---|---|---|---|---|---|
| Clinician (MD/DO/NP/PA) | Visitron | ProviderAppointments, PatientAppointments, requestChatVisit, getChatHistory, getDraftEncounter, publishDraftEncounter |
Review chart, conduct video/chat, decide tirzepatide, order labs, draft/finalize Rx, sign care plan | Video promise “today”; chat next window 10:00 MT; shift-based | [LIVE /api/external/sku_options/300543]; [DATA internal_portals_recon.json → visitron]; [LIVE /clinician-hiring] |
| Clinical reviewer (ACR) | Visitron | getAsyncClinicalReview, submitAsyncClinicalReview, getAsyncClinicalReviewFileUploadPreview, getClinicianReviews, applyReview, rejectReview, confirmNoChange |
Review async submissions, request photos/files, approve/deny, escalate to 300591 if red flag | Unknown; ACR is enabled per price option and GLP-1 eval has no ACR option | [DATA internal_portals_recon.json → visitron]; [CODE types/enums/sku-constants.ts:7-8]; [DOC architecture.md §10.3] |
| Care coordination / ops | Nile-Core + Message Center + Referrals | conversations, conversation_subjects (includes pharmacy_order), response_expectation; Referrals promises queue |
PA follow-up, pharmacy issues, reschedule, refill exceptions, patient messages | response_expectation is dynamic per thread; support Mon–Fri 9–9 ET |
[CODE lib/api/endpoints.ts:60-65]; [CODE lib/store/api/messageCenterApi.ts:19]; [DOC architecture.md §10.7]; [LIVE /faq] |
| Pharmacist (LillyDirect dispensing pharmacy) | Amazon/Fuze/Gifthealth/Prescryptive/Walmart | Pharmacy system + checkout link | Verify Rx, check insurance/PA, apply savings, collect payment, ship/pickup | 3–5 business days to contact; 1–4 days to ship after checkout | [LIVE LillyDirect FAQ] |
| Retail pharmacist | CVS/Walgreens/Walmart | Pharmacy system | Adjudicate claim, dispense, counsel, collect copay or GM card | Same day–2 days (inferred) | [INFERENCE]; [LIVE /pharmacy/walgreens-pharmacy/73542] |
| Medical Director | Emerald PCs | Governance/sign-off | Clinical oversight, protocol approval, GLP-1 guide review | Not queue-based | [LIVE GLP-1 guide byline Dr. Pallabi Sanyal-Dey]; [DOC adversarial-and-market-report.md §3.1] |
| Credentialing / licensure | GM + PCs | getStateOptions, appointment_location_state, practiceId |
Maintain state→clinician→PC matrix; block unsupported states | Per-state; not observable | [DATA internal_portals_recon.json → visitron]; [CODE lib/routes/skuBooking.ts:53-59] |
| Finance | GM | Stripe dashboard; invoice, gm_card |
Reconcile visit/pharmacy payments, refunds, cancellation fees, chargebacks | Refunds 5–10 business days | [LIVE /cancellation-policy, 2026-10-19] |
| Patient support | GM | SMS 98528; help@generalmedicine.co; Message Center |
Triage visit/pharmacy/PA issues | Mon–Fri 9–9 ET | [LIVE /faq; /using-zoom; /cancellation-policy] |
| Engineering on-call | GM | Visitron/Nile-Core | Athena/DoseSpot/Arrive/Nabla outage; stuck encounters; eRx failures | Unknown | [INFERENCE] from integration chokepoint; [DOC architecture.md §8.2] |
Shift mechanics. Visitron has getPendingShiftCheckouts, createShiftCheckout, getShiftCheckoutStatus, extendChatShift, reclaimFinishedChatVisit, cancelWithoutFee, markVisitNoShow, rescheduleSameProvider, rescheduleAnyProvider. This is a shift-based clinical labor model, not a salaried panel. The hiring page confirms 1099 flexibility, “pick your own hours”, “employed provider group” + “contractor clinicians”. [DATA internal_portals_recon.json → visitron]; [LIVE /clinician-hiring]
4. Money
4.1 Visit fees (the clinical gate)
| Item | Cash | Insurance | Notes | Evidence |
|---|---|---|---|---|
GLP-1 medication evaluation 300543 — video |
$100.00 | $25.00 est. | Insured price is an estimate; actual copay after claim | [LIVE /api/external/sku_options/300543, 2026-10-19]; [LIVE /s/glp-1-medication-evaluation/300543] |
GLP-1 medication evaluation 300543 — chat |
$30.00 | none | Cash-only; no insurance sub-option | [LIVE /api/external/sku_options/300543] |
Weight Loss Follow-Up 300550 — video |
$100.00 | $25.00 est. | Same structure; used for week-4 titration | [LIVE /api/external/sku_options/300550]; [LIVE /s/weight-loss-follow-up/300550] |
Weight Loss Follow-Up 300550 — chat |
$30.00 | none | Cash-only | [LIVE /api/external/sku_options/300550] |
| Typical visit copay | — | $25.00 | TYPICAL_VISIT_COPAY_CENTS = 2500; used for logged-out display and fallback |
[CODE lib/productDetailPage/resolveMedicationOptionVisitCost.ts:4] |
| Cancellation / no-show fee | $25.00 default | — | Client fallback 2500; fee-eligible visit types are video only (video_visit, video_visit_with_specialist_consultation), not chat; triggers: late_customer_cancel, no_show, no_show_predicted, no_confirmation, no_id_verification, missing_insurance; Medicaid patients exempt per live policy |
[CODE utils/cancellationFeeUtils.ts:6-26, 43-53]; [LIVE /cancellation-policy, 2026-10-19] |
| HSA/FSA | Eligible | Eligible | GM card purchases are HSA/FSA eligible | [LIVE pay-ahead article, 2026-10-05] |
Practical read. For an insured patient, video ($25) is cheaper than chat ($30). Chat is a cash convenience, not a discount. The 4-week titration visit adds another $25–$100, so the clinical gate alone is $50–$200 over the first two months, before drug cost.
4.2 Drug prices by channel (live, 2026-10-19)
All values are 28-day supply. “GM cash” is the live /api/external/medication_option_skus/:id/cash_price; “retail” is the live /api/external/pharmacy_comparisons row at San Francisco coordinates. Prices move; re-probe before quoting.
| Drug / form | GM cash | Manufacturer-direct / card | Walgreens | CVS | Notes |
|---|---|---|---|---|---|
Zepbound KwikPen 2.5 mg (710641) |
$299.00 | LillyDirect $299.00; Amazon $299.00 | $496.12 | $508.09 | GM price = Lilly self-pay card price; retail is ~66–70% higher |
Zepbound KwikPen 5 mg (710643) |
$399.00 | LillyDirect $399.00 | $496.12 | $508.09 | Retail flat at the 7.5 mg-tier price |
Zepbound KwikPen 7.5 mg (710644) |
$449.00 | LillyDirect $449.00 | $496.12 | $508.09 | 45-day refill condition for $449 |
Zepbound KwikPen 10/12.5/15 mg (710647/710654/710651) |
$449.00 | LillyDirect $449.00 | $692.92 | $709.69 | 45-day refill condition |
Zepbound auto-injector 2.5–15 mg (710642/710646/710649/710652/710658/710661) |
$1,074.09 | Single-dose pen card: $25 covered / $499 not covered | $1,074.09 | $1,100.16 | Default PDP form; single-dose pen, not KwikPen |
Zepbound single-dose vial 2.5–15 mg (701542/706142/704052/706624/708202/701128) |
null | LillyDirect self-pay (public Dec-2025 price cut: $299/$399/$449; not live-verified on GM) | null | null | GM shows “Priced after visit”; no LillyDirect row in comparison |
Mounjaro auto-injector 2.5–15 mg (710655/710657/710662/710663/710664/710667) |
$552.28 | No LillyDirect listing | $552.28 | $565.63 | T2D brand; retail only |
Foundayo (orforglipron) oral (706450) |
$149.00 | LillyDirect $149.00; Amazon $149.00 | $643.72 | $659.29 | Lilly oral GLP-1 |
Wegovy (injectable) (709551) |
$149.00 | NovoCare $149.00 | $1,332.53 | $1,364.91 | Novo direct-pay; PDP short description says weekly injection — verify form before quoting |
Ozempic (semaglutide, T2D) (711204) |
$199.00 | NovoCare $199.00 | null | null | Retail unpriced in this zip |
The key price fact. GM’s “from $299” is consistent with a manufacturer self-pay pass-through, not a GM-negotiated retail discount. At retail, the GM card price for the same 2.5 mg KwikPen is $496.12 (Walgreens) / $508.09 (CVS), which is higher than the 5 mg self-pay price ($399) and close to the 7.5 mg regular price ($499). The cheapest path is to route the Rx to LillyDirect (or Amazon/NovoCare), not to use the GM card at a retail counter. [LIVE cash_price and pharmacy_comparisons, 2026-10-19]; [PUBLIC Zepbound savings terms: regular price $299/$399/$499/$699]
4.3 The three cash/insurance rails (and a fourth)
| Rail | Billing type | What the patient pays | Where | Code/evidence | Operational consequence |
|---|---|---|---|---|---|
| A. Cash pre-pay / GM card | client gm_card; server cash |
GM cash price at checkout | Stripe → GM; pharmacy told “prepaid”; virtual card texted | [CODE lib/utilities.ts:949-955]; [CODE pharmacyOrderApi.ts:61-72]; [LIVE pay-ahead article] |
Pay-ahead works at eligible retail pharmacies only; not mail order. GM must reconcile every prepaid claim. |
| B. Insurance | insurance |
Copay at counter (no app charge) | PBM adjudication; pharmacy collects | [CODE pharmacyOrderApi.ts:73-80]; [DOC architecture.md §9.1 step 4] |
PA may be required; GM’s estimate is not a guarantee; savings card may reduce at counter. |
| C. Pharmacy delegation | client pharmacy_delegated; server pharmacy_delegation |
Discounted price at pharmacy | Patient pays pharmacy; GM card BIN/PCN/group/member | [CODE lib/utilities.ts:952-953]; [CODE pharmacyOrderApi.ts:81-88, 105-110]; [DOC openapi.yaml:1390-1420] |
GM does not take custody of drug or payment (per dossier); pharmacy claims through GM’s switch. |
| D. Mail order (LillyDirect/Amazon/NovoCare) | pharmacy_delegation (inferred) |
Manufacturer self-pay price, paid to the pharmacy | Pharmacy checkout link | [LIVE LillyDirect FAQ]; [INFERENCE] mapping to pharmacy delegation |
No GM pay-ahead; patient pays a third party; GM’s order record does not show payment. |
The “General Medicine card” is two different artifacts. The public article shows a card and says the pharmacy is told the Rx is prepaid; the API’s gm_card is a BIN/PCN/group/member_id pharmacy discount/claim-routing card. A prepaid payment card and a discount card are not the same instrument. The article uses one name for both. Build two distinct objects in the tech plan: (1) virtual payment card/Stripe charge, (2) discount/claim card. [LIVE pay-ahead article]; [DOC openapi.yaml:1390-1420]; [INFERENCE]
4.4 Manufacturer savings cards
Zepbound KwikPen Self-Pay Savings Card (the card that produces GM’s $299/$399/$449):
- 2.5 mg: as low as $299, max monthly savings $215.
- 5 mg: as low as $399, max monthly savings $115.
- 7.5/10/12.5/15 mg: as low as $449; first purchase qualifies, then refill within 45 days of the previous delivery.
- Regular price outside the offer: $299 / $399 / $499 / $699 / $699 / $699 for 2.5/5/7.5/10/12.5/15 mg.
- Cash only, outside any health insurance; patient agrees not to seek reimbursement from any payer, including private insurance or government programs; “THIS CARD IS NOT INSURANCE.”
- Expires 12/31/2026.
- Post-transaction reimbursement runs through EVERSANA (eversana-ptr.virtualrx.co).
[PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]
On-label requirement. Both savings programs require a prescription for an “approved use consistent with FDA-approved product labeling.” An off-label BMI <27 prescription is not eligible for the Lilly self-pay/card price; the patient is in a retail-cash or insurance-denial path. [PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]; [LIVE GLP-1 guide]
Zepbound Single-Dose Pen (auto-injector) Savings Card:
- Covered commercial: as low as $25 per 1/2/3-month fill (max $100/$200/$300; $1,300/calendar year; 13 fills).
- Not-covered commercial: as low as $499 per month.
- Excludes Medicare/Medicaid/TRICARE/VA/etc.
[PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]
Medicare GLP-1 Bridge: eligible Medicare Part D patients with a Zepbound weight-management prescription may pay no more than $50/month; eligibility based on clinical criteria; not a guarantee of coverage. [PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]
What GM’s software does with these: nothing observed. There is no savings-card field, BIN/PCN for a manufacturer card, or PTR object in the consumer API or Visitron. LillyDirect’s dispensing pharmacies apply eligible savings automatically; a retail pharmacy can apply a manufacturer card at the counter if the patient enrolled. GM’s insurance estimate may not reflect the card. [INFERENCE] from absence of fields + [LIVE LillyDirect FAQ] (“the dispensing pharmacy filling your prescription will apply the savings card automatically”)
4.5 Shipping, cold chain, and fees
- LillyDirect home delivery is free. Most prescriptions process/ship 1–4 days after checkout; verification/checkout link takes 3–5 business days after the Rx arrives.
[LIVE LillyDirect FAQ] - Cold chain: refrigerated medicines ship in cold-chain packaging; may not ship near weekends/holidays. Most shipments do not require a signature.
[LIVE LillyDirect FAQ] - Label storage: Zepbound and Mounjaro single-dose pens/vials 2–8°C (36–46°F); up to 21 days at ≤30°C (86°F), one-way (do not return to refrigerator).
[PUBLIC Zepbound SPL §16.2];[PUBLIC Mounjaro SPL §16.2] - Retail pickup: no shipping; patient picks up; pharmacy handles temperature during storage.
- GM fees: no shipping fee observed; no GM tracking/carrier field in
PharmacyOrder.[DOC openapi.yaml:243-273] - Cancellation/refund: fee charged to card on file; visit fees refunded automatically if fee applies; refunds 5–10 business days; no refunds for services provided or cancellation fees; Medicaid exempt.
[LIVE /cancellation-policy] - ACR clinical review fee (not GLP-1): in-person SKUs can bundle
coordination_fee+clinical_review_feeintocheckout_fee; live300603= $30 + $15 = $45, withallows_acr: true.[LIVE /api/external/sku_options/300603];[CODE OfficeVisitOption.tsx:52-57]
4.6 What GM earns on the pharmacy leg
Unknown. The $299/$399/$449 Zepbound prices equal Lilly’s self-pay prices, which is consistent with a pass-through rather than a GM margin. The retail GM-card price is higher, consistent with a discount-card/claim-switch economics, but no fee, spread, or remittance field is exposed in the recovered source. Do not model pharmacy gross margin without a contract. [INFERENCE] from price equality + absence of fields.
5. Failure modes & branches
5.1 Clinical branches
| Branch / failure | What happens | Evidence |
|---|---|---|
| Zepbound BMI <27 | Not on-label for Zepbound weight management; clinician may discuss off-label, typically not covered by insurance, and not eligible for the Lilly self-pay/card price (requires an approved-use prescription). Mounjaro (T2D) has no BMI threshold. | [LIVE GLP-1 guide] (BMI table); [PUBLIC Zepbound SPL §1]; [PUBLIC savings terms] |
| Zepbound BMI 27–29.9 without comorbidity | Not on-label; off-label/insurance denial likely; cash path may be retail, not the Lilly self-pay card. | [PUBLIC Zepbound SPL §1]; [LIVE GLP-1 guide]; [PUBLIC savings terms] |
| Label §4 contraindication: MTC/MEN2 | Do not prescribe tirzepatide: personal or family history of medullary thyroid carcinoma, or MEN 2. | [PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §4] |
| Label §4 contraindication: serious hypersensitivity | Do not prescribe: known serious hypersensitivity to tirzepatide or any excipient (anaphylaxis/angioedema reported). | [PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §4, §5.6] |
| Label precautions (not §4) | Severe gastroparesis (not recommended), acute pancreatitis (discontinue if suspected), acute gallbladder disease, AKI from volume depletion, hypoglycemia with insulin/secretagogue, diabetic retinopathy in T2D, pulmonary aspiration under anesthesia, pregnancy (may cause fetal harm; discontinue when recognized). Clinician judgment/monitoring, not an automatic contraindication. | [PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §5, §8.1] |
| GM protocol screening exclusion (not label §4) | Active eating disorder / significant body-image concerns; GM’s clinical-protocol exclusion. | [LIVE GLP-1 guide] |
| Abnormal baseline labs | Hold/adjust; repeat labs; may delay first fill. | [LIVE GLP-1 guide] (baseline and 3–6 month repeat); [INFERENCE] |
| Patient on another GLP-1 | Clinician may switch; label says coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. | [PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §1 Limitations of Use]; [LIVE GLP-1 guide] |
| Under 18 | Not eligible for GM; adult-only service. | [LIVE /faq] |
| State not supported | Booking/state confirmation should block; exact copy not recovered. | [CODE lib/routes/skuBooking.ts:53-59]; [INFERENCE] |
5.2 Insurance / PA branches
| Branch / failure | What happens | Evidence |
|---|---|---|
| PA required | RTPB flags it; GM/LillyDirect/pharmacy coordinates; several business days; patient may wait. | [LIVE GLP-1 guide]; [LIVE LillyDirect FAQ]; [LIVE Zepbound PDP FAQ] (“prior authorization is commonly required”) |
| PA denied | Cash/self-pay or alternative; GM testimonial claims follow-through after denial, but no PA appeal object/queue exists in recovered software. | [CODE testimonials.ts:50,61]; [DATA visitron ops]; [INFERENCE] manual |
| Plan does not cover weight management | Cash path; Medicare Part D usually does not cover Zepbound for weight management alone. | [LIVE Zepbound PDP FAQ]; [LIVE GLP-1 guide] |
| Medicare Part D | Possible GLP-1 Bridge ≤$50/mo if eligible; otherwise cash/self-pay. | [PUBLIC zepbound.lilly.com/savings] |
| Medicaid | Cancellation fee exempt; GLP-1 coverage varies; manufacturer savings cards exclude government payers. | [LIVE /cancellation-policy]; [PUBLIC savings terms] |
| Insurance estimate wrong | Patient sees “est.” price; actual copay set at adjudication; GM’s tooltip says price is only known after prescription. | [CODE MedicationPriceCard.tsx:14-15]; [LIVE PDP] (“Available after visit”) |
| Patient selects LillyDirect while insured | LillyDirect self-pay is cash-only; patient agrees not to seek insurance reimbursement; no PA needed. For insurance, the patient should use a retail pharmacy or a LillyDirect insurance-eligible medicine. [INFERENCE] from the self-pay terms. |
[LIVE LillyDirect FAQ]; [PUBLIC savings terms] |
| Patient selects Walmart pickup via LillyDirect | $299 self-pay; patient agrees not to seek reimbursement; this is a different channel from Walmart retail (NCPDP 0511053, $496.12). | [LIVE LillyDirect FAQ]; [LIVE pharmacy_comparisons 710641] |
PA read (direct answer). The only PA-adjacent software on this path is the RTPB layer: Arrive Health (launch_benefit_inquiry) and DoseSpot (prescription_eligibility_inquiries/*) return copay/formulary/PA requirements; neither exposes a PA submission or appeal object in the recovered ops. There is no CoverMyMeds/Surescripts integration in source or DNS. Who files is therefore not established: GM marketing says it handles PAs, the Assignment of Benefits says the patient/referring physician is responsible, and LillyDirect says it coordinates PAs with the provider and insurer. Timing: “several business days” (GM GLP-1 guide); LillyDirect allows 3–5 business days for Rx verification before its checkout link. Model PA as a manual ops queue with a case record you build, not as a recovered GM workflow. [CODE lib/hardcoded-data/CategoryPages/medications.ts:43]; [LIVE /assignment-of-benefits]; [LIVE GLP-1 guide]; [LIVE LillyDirect FAQ]; [DATA internal_portals_recon.json → visitron]
5.3 Fulfillment / pharmacy branches
| Branch / failure | What happens | Evidence |
|---|---|---|
| Patient selects auto-injector (default PDP) | Pays $1,074.09 (Walgreens/Walmart) or $1,100.16 (CVS), not $299. The single-dose pen is not the KwikPen self-pay tier. | [LIVE PDP selected_sku_id=710642; cash_price=107409]; [PUBLIC savings terms] |
| Patient selects vial | No GM cash price; “Priced after visit”; not routed to LillyDirect; retail comparison all null. | [LIVE 701542 cash_price=null]; [LIVE comparison 701542] |
| Patient selects Mounjaro | Retail only; no LillyDirect; $552.28 cash at Walgreens, $565.63 at CVS; insurance/PA for T2D. | [LIVE 710655]; [LIVE LillyDirect medications list] |
| Out of stock at retail | No inventory signal in GM; patient/pharmacy must discover it; remedy is cancel/switch pharmacy or wait. | [LIVE comparison fields: no in_stock]; [CODE cancel + can_switch_pharmacy] |
| Out of stock at LillyDirect | LillyDirect says prescriptions can still be filled with a slight delay during limited availability; no GM substitution logic. | [LIVE LillyDirect FAQ] |
| Pharmacy never receives eRx | Patient sees no fill; must text 98528 / message; GM has no eRx acknowledgment field in the consumer schema; known 1-star complaint pattern. | [LIVE /using-zoom; /faq]; [DOC adversarial-and-market-report.md §5.5]; [INFERENCE] |
| Claim rejected at counter | Patient pays cash or resolves PA; GM’s app has no claim-rejection state. | [INFERENCE]; [DOC PharmacyOrder state model] |
| Patient wants to switch pharmacy after order placed | POST /pharmacy_orders/:id/cancel { pharmacyChange: true }; response returns can_cancel_pharmacy_order, can_switch_pharmacy, can_choose_new_pharmacy; may require new order. |
[CODE pharmacyOrderApi.ts:12-24, 46-59]; [DOC architecture.md §9.1 step 6] |
| Patient wants to transfer an existing Rx | No transfer API. “Request a prescription” starts a clinical review/booking flow; LillyDirect says ask the provider to send a new Rx; retail-to-retail transfer is pharmacy-mediated. | [CODE RequestPrescriptionCard.tsx:47-66]; [LIVE LillyDirect FAQ]; [LIVE /pharmacy/walgreens-pharmacy/73542] (“Start with a clinical review”) |
| Dose change at week 4 | Pharmacy will not auto-adjust; each new dose needs a new Rx. If the patient misses the check-in, no refill. | [LIVE LillyDirect FAQ] (“Each new dose typically requires an updated prescription”); [PUBLIC Zepbound SPL §2.2] |
| Refill with no refills left | Clinician renewal required; may require questionnaire/labs/visit. | [CODE lib/hardcoded-data/CategoryPages/medications.ts:160-161]; [LIVE /resources/medication-faqs] |
| Cold-chain failure | Replace via pharmacy; no GM tracking/temperature telemetry. | [LIVE LillyDirect FAQ]; [PUBLIC label]; [INFERENCE] |
5.4 Software / contract risks exposed by this file
| Risk | Why it matters | Evidence |
|---|---|---|
Billing-type enum mismatch (gm_card/pharmacy_delegated vs cash/pharmacy_delegation) |
A branch may never fire or may send an invalid enum; pharmacy payment logic is the highest-risk place for a silent bug. | [CODE lib/utilities.ts:949-955]; [DOC openapi.yaml:257-262, 1241-1246] |
hasClinicalReview source unknown |
billingTypeRequiresPayment depends on it for insurance/pharmacy-delegation; no field in PharmacyOrder schema. |
[CODE lib/utilities.ts:949-955]; [DOC openapi.yaml:243-273] |
default_quantity unit inconsistency |
Could generate a 14-day Mounjaro supply or a 56-day Zepbound supply; pharmacy may correct silently, masking the defect. | [LIVE PDP 710642, 710655] |
201448 first-fill=false |
New patient can be routed to a SKU that does not allow first fill from the Lilly page; may dead-end or misclassify intake. | [DATA 201448.modalities]; [LIVE Lilly page] |
No in_stock |
Cannot automate out-of-stock routing; ops must call/switch. | [LIVE comparison fields] |
No tracking/carrier in PharmacyOrder |
Patient support cannot answer “where is my package?” from GM data; must use pharmacy. | [DOC openapi.yaml:243-273] |
| Chat price fallback $35 | Code fallback is $35; live price is $30. If the price payload misses, the user sees the wrong price. |
[CODE components/VisitOptions/ChatVisitOption.tsx:32]; [LIVE 3000] |
| No PA object | PA work is invisible to analytics and SLAs; cannot measure denial/appeal rates. | [DATA visitron; consumer endpoints] |
| No manufacturer savings-card field | Cannot show the real out-of-pocket (e.g., $25 with Zepbound card) or reconcile PTR. | [INFERENCE] from absence; [PUBLIC savings terms] |
| Two telehealth consents (Emerald vs Vital/OpenLoop) | Which entity furnishes a given GLP-1 visit is not determinable; consent/records/billing may be misattributed. | [LIVE /telehealth-informed-consent; /vital-informed-consent] |
| PC state list vs NPPES mismatch | Compliance/credentialing risk; state→PC matrix cannot be trusted from either source alone. | [LIVE ToS/consent]; [PUBLIC NPPES] |
6. Open questions
- State→PC mapping. Which Emerald PC furnishes a GLP-1 visit in each state, and is the
practiceIdin the booking flow a PC ID, a tenant ID, or a clinician-group ID? The client only carries the value; the assignment is server-side. - OpenLoop/Vital role. Is the Vital/OpenLoop/Reliant/MECNB consent used for GLP-1 visits in states without an Emerald PC, or is it legacy/for another service line? Two telehealth consents coexist.
- Async GLP-1 review. Does any GLP-1 case use
AsyncClinicalReviewbefore/after the video/chat visit? The SKU has noallows_acr, but the FAQ advertises an “asynchronous consult within 24–48 hours” after General AI. Is that a different product or the same chat modality? - PA vendor and queue. Who actually submits the PA (GM ops, clinician, retail pharmacy, LillyDirect dispensing pharmacy)? Is Arrive Health’s ePA module used, or only RTPB? Is there a denial/appeal queue? No PA object exists in the recovered software.
- PA timing. GM says “several business days”; LillyDirect says 3–5 business days for Rx verification; what is the measured p50/p90 for GLP-1 PA?
- Pharmacy economics. Does GM earn a spread, a discount-card fee, or a manufacturer/partner fee on any pharmacy leg? The $299 price equality suggests pass-through, but there is no contract evidence.
- Manufacturer savings cards in GM checkout. Can a patient attach a Zepbound/Novo savings card in GM’s insurance path, or only at the pharmacy counter? No field exists.
- Week-4 requirement. Is the 4-week titration step a paid follow-up visit (
300550), a questionnaire-only check-in, or either? The label requires a dose decision; the CareJourney can gate on Questionnaire, Lab, or Visit. - Clinical SLAs. What are the promised response times for chat visits, video starts, ACR decisions, and PA updates?
response_expectationis dynamic; no static SLA is published. - Out-of-stock handling. Is there a pharmacy status feed (NCPDP/NCPDP SCRIPT confirmation, backorder, partial fill) that GM consumes server-side but does not expose? The client has no
in_stockor rejection state. - Tracking. Does GM ingest carrier/tracking from LillyDirect/Amazon/retail?
PharmacyOrderhas no tracking fields. - Quantity unit. Is
default_quantitymL or pens? Mounjaro’s1.0for 28 days is inconsistent with a 4-pen supply. - Default form intent. Why is the Zepbound PDP default the auto-injector ($1,074.09) rather than the KwikPen ($299)? Is this a clinical default (single-dose pen preferred) or a catalog artifact?
201448CTA. Is the Lilly page’s Zepbound CTA to afirst_fill:falseSKU intentional (existing patients) or a funnel bug for new starts?- Transfer flow. Can a patient move an existing Rx from another pharmacy without a new GM visit? The only observed path is a new clinical review/Rx.
- LillyDirect insurance eligibility. LillyDirect accepts insurance for “select medicines”; which GLP-1 SKUs are insurance-eligible vs self-pay-only? GM’s comparison does not label this.
- Who collects the $299. Does GM collect the KwikPen self-pay price and remit to LillyDirect, or does the patient pay LillyDirect directly? The public article says pay-ahead is retail-only; the order schema does not distinguish.
gm_cardfunding. Who sponsors the BIN/PCN, what is the discount formula, and is the card the same instrument as the “prepaid” card in the article?- Clinical review fee applicability. Does a GLP-1 pharmacy order ever carry a
clinical_review_fee(e.g., questionnaire-only renewal), or is the visit fee the only clinical charge? - ACR for GLP-1 in any state. Could a state or protocol route a GLP-1 case through ACR despite the current SKU configuration? The SKU data says no; the Visitron capability exists.
pharmacy_delegatedenum. Is the client literal a typo, a legacy alias, or the actual server value? This must be resolved before building payment reconciliation.- Pharmacy directory indexing. The directory pages are
noindex,nofollow; are they intended as SEO surfaces or only in-app navigation? (Acquisition file.)
7. Handoff to other evidence files
- Handoff to Acquisition: The Lilly partner page’s Zepbound CTA goes to
201448(allows_first_fill:false,allows_refill:true), while the new-start path is300543. The page advertises “from $299” but the default PDP is the auto-injector at $1,074.09. Fix or explain before scaling paid traffic. Also: pharmacy directory pages arenoindex,nofollow. - Handoff to Intake: State confirmation and
practiceIdare the only visible routing signals; the questionnaire UUIDs for300543are11340c6b-1296-4c46-ad5b-1e9c48474084(screening) and3cdcfa37-64a0-4257-964b-9a41209b1f29(history), and for201448e286b849-9076-44f3-bd2b-a590d877495a/140be43a-30ca-44e0-95b3-dfb3f5cbc839. Use these to join intake answers to the clinical decision.[DATA extracted_care_plans_and_journeys.json] - Handoff to FirstMonth: The week-4 state is a CareJourney check-in (
/prescriptions/:id/check-in) plus a possible300550visit and a new Rx for 5 mg. The 5 mg KwikPen cash price is $399; the auto-injector is $1,074.09; insurance copay depends on PA. Build the titration reminder around the label’s 4-week step, not a generic 30-day refill. - Handoff to CheckoutLabs: The three billing rails (
gm_card/cash,insurance,pharmacy_delegated/pharmacy_delegation), the $25 default cancellation fee (video only), and the pay-ahead vs pay-at-pharmacy split all need one owner. The enum mismatch andhasClinicalReviewsource are blockers for a clean payment model. - Handoff to Backoffice: Visitron is the integration chokepoint: Athena, DoseSpot, Nabla, Arrive, Metriport. The shift/checkout model and provider notifications are the clinician queue. PA work has no object; it needs a queue/tool and an SLA before the operating plan can staff it.
Source appendix (live probes and public sources)
All live GETs were unauthenticated, read-only, and made 2026-10-19 PT / 2026-10-20 UTC. No account, form, checkout, or personal data was submitted.
https://generalmedicine.co/s/glp-1-medication-evaluation/300543https://generalmedicine.co/s/weight-loss-follow-up/300550https://generalmedicine.co/s/zepbound-tirzepatide/201448→/dp/zepbound/710642https://generalmedicine.co/s/mounjaro-tirzepatide/201446→/dp/mounjaro/710655https://generalmedicine.co/dp/zepbound/710642https://generalmedicine.co/p/lilly/weight-losshttps://generalmedicine.co/pharmacy/lillydirect/88334https://generalmedicine.co/pharmacy/walgreens-pharmacy/73542https://generalmedicine.co/api/external/sku_options/{300543,300550,201448,300603}https://generalmedicine.co/api/external/product_detail_pages/{710642,710655}https://generalmedicine.co/api/external/medication_option_skus/{710641,710642,710643,710644,710646,710647,710649,710651,710652,710654,710658,710661,701542,706142,704052,706624,708202,701128,710655,710657,710662,710663,710664,710667,706450,709551,711204}/cash_pricehttps://generalmedicine.co/api/external/pharmacy_comparisons?medication_option_sku_id={710641,710642,701542,710655,706450,709551,711204}&latitude=37.7749&longitude=-122.4194https://generalmedicine.co/api/external/pharmacy_detail_pages/{88334,36035,84293}https://generalmedicine.co/api/external/pharmacy_detail_pages/88334/medications?page=1&per_page=50https://generalmedicine.co/api/external/search/index?query={compounded,tirzepatide,semaglutide,zepbound,mounjaro}https://generalmedicine.co/terms-of-servicehttps://generalmedicine.co/telehealth-informed-consenthttps://generalmedicine.co/vital-informed-consenthttps://generalmedicine.co/assignment-of-benefitshttps://generalmedicine.co/cancellation-policyhttps://generalmedicine.co/faqhttps://generalmedicine.co/resources/using-a-glp-1-for-weight-losshttps://generalmedicine.co/resources/medication-faqshttps://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickuphttps://generalmedicine.co/clinician-hiringhttps://generalmedicine.co/using-zoomhttps://www.lilly.com/lillydirect/faqhttps://zepbound.lilly.com/savingshttps://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html(public report of the Dec-2025 vial price cut; Lilly investor PDF returned 403)https://npiregistry.cms.hhs.gov/api/?number={1912889320,1285084467,1710671854,1447011267,1750195483,1174333975,1346050150}&version=2.1https://api.fda.gov/drug/label.json?search=openfda.brand_name:"ZEPBOUND"and"MOUNJARO"https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/{d2d7da5d-ad07-4228-955f-cf7e355c8cc0}.xmlhttps://www.pharmacytimes.com/view/manufacturer-bypasses-traditional-channels-to-sell-directly-to-patients-and-it-makes-perfect-sensehttps://corporate.walmart.com/news/2025/10/29/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consumer-pricing-for-zepbound